Denali Therapeutics Inc.

DNLI

$17.37

Name : Denali Therapeutics Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $2,547,516,160.00

EPSttm : -2.92

Denali Therapeutics Inc.

$17.37

0.40%

$0.07

Float Short %

9.98

Margin Of Safety %

Put/Call OI Ratio

0.75

EPS Next Q Diff

-0.03

EPS Last/This Y

-0.45

EPS This/Next Y

0.08

Price

17.36

Target Price

31.6

Analyst Recom

1.06

Performance Q

17.33

Relative Volume

0.6

Beta

1.11

Ticker: DNLI

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	DNLI	17.25	0.44	0.10	1601
2025-10-21	DNLI	16.97	0.42	0.00	1654
2025-10-22	DNLI	15.99	0.41	0.39	1701
2025-10-23	DNLI	15.88	0.42	0.44	1752
2025-10-24	DNLI	15.94	0.42	0.11	1773
2025-10-27	DNLI	16.2	0.42	0.05	1787
2025-10-28	DNLI	16.92	0.42	0.00	1795
2025-10-29	DNLI	16.26	0.42	0.21	1773
2025-10-30	DNLI	16.38	0.42	0.00	1779
2025-10-31	DNLI	16.28	0.42	20.50	1782
2025-11-03	DNLI	15.36	0.41	8.37	1777
2025-11-04	DNLI	14.9	0.63	35.67	2077
2025-11-05	DNLI	14.89	0.79	0.75	2302
2025-11-06	DNLI	14.84	0.79	0.00	2309
2025-11-07	DNLI	15	0.79	0.00	2309
2025-11-10	DNLI	15.61	0.78	0.08	2318
2025-11-11	DNLI	17.59	0.79	0.04	2320
2025-11-12	DNLI	17.53	0.79	0.03	2335
2025-11-13	DNLI	17.15	0.76	0.00	2392
2025-11-14	DNLI	17.44	0.76	0.06	2392
2025-11-17	DNLI	17.37	0.75	0.00	2414
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	DNLI	17.25	-20.1	206.7	-3.03
2025-10-21	DNLI	16.97	-20.1	231.2	-3.03
2025-10-22	DNLI	15.95	-20.1	251.7	-3.03
2025-10-23	DNLI	15.87	-20.1	225.9	-3.03
2025-10-24	DNLI	15.94	-20.1	221.6	-3.03
2025-10-27	DNLI	16.20	-20.1	216.2	-3.03
2025-10-28	DNLI	16.92	-20.1	202.2	-3.03
2025-10-29	DNLI	16.28	-20.1	241.5	-3.03
2025-10-30	DNLI	16.38	-20.1	220.5	-3.03
2025-10-31	DNLI	16.28	-20.1	226.2	-3.03
2025-11-03	DNLI	15.36	-20.1	250.6	-3.03
2025-11-04	DNLI	14.89	-20.1	238.9	-3.03
2025-11-05	DNLI	14.89	-20.1	224.7	-3.03
2025-11-06	DNLI	14.41	-20.1	239.7	-3.03
2025-11-07	DNLI	15.02	-20.4	201.6	-3.04
2025-11-10	DNLI	15.60	-15.3	218.9	-3.04
2025-11-11	DNLI	17.58	-18.7	177.8	-3.01
2025-11-12	DNLI	17.52	-18.7	239.5	-3.01
2025-11-13	DNLI	17.14	-18.6	224.8	-3.04
2025-11-14	DNLI	17.44	-18.6	206.0	-3.04
2025-11-17	DNLI	17.36	-17.3	216.4	-3.02
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	DNLI	-3.16	2.66	10.82
2025-10-21	DNLI	-3.16	2.66	10.82
2025-10-22	DNLI	-3.16	2.66	10.82
2025-10-23	DNLI	-3.16	2.66	10.82
2025-10-24	DNLI	-3.16	2.66	10.82
2025-10-27	DNLI	-3.16	2.56	11.10
2025-10-28	DNLI	-3.16	2.56	11.10
2025-10-29	DNLI	-3.10	2.56	11.13
2025-10-30	DNLI	-3.10	2.56	11.13
2025-10-31	DNLI	-3.10	2.56	11.10
2025-11-03	DNLI	-3.16	2.63	11.10
2025-11-04	DNLI	-3.16	2.63	11.10
2025-11-05	DNLI	-3.16	2.63	11.10
2025-11-06	DNLI	-3.16	2.63	11.10
2025-11-07	DNLI	-3.16	2.63	11.11
2025-11-10	DNLI	-3.14	3.56	11.07
2025-11-11	DNLI	-3.14	3.56	11.07
2025-11-12	DNLI	-3.14	3.56	9.99
2025-11-13	DNLI	-3.14	3.56	9.99
2025-11-14	DNLI	-3.14	3.56	9.98
2025-11-17	DNLI	-3.19	5.50	9.98
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.74

Avg. EPS Est. Current Quarter

-0.79

Avg. EPS Est. Next Quarter

-0.77

Insider Transactions

-3.19

Institutional Transactions

5.5

Beta

1.11

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

81.5

Max Drawdown 5-Year %

-87.7

Target Price

31.6

P/E

Forward P/E

PEG

P/S

P/B

2.75

P/Free Cash Flow

EPS

-2.91

Average EPS Est. Cur. Y

-3.02

EPS Next Y. (Est.)

-2.94

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.6

Return on Equity vs Sector %

-80.8

Return on Equity vs Industry %

-65.9

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

216.4

Denali Therapeutics Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 517

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

stock quote shares DNLI – Denali Therapeutics Inc. Stock Price stock today

news today DNLI – Denali Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch DNLI – Denali Therapeutics Inc. yahoo finance google finance

stock history DNLI – Denali Therapeutics Inc. invest stock market

stock prices DNLI premarket after hours

ticker DNLI fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: DNLI

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y